Solid Biosciences' IPO

Solid Biosciences raised a round of funding on January 26, 2018. Investors include Public.

Solid Biosciences is a gene therapy platform focused on developing novel, disease-modifying therapeutics for Duchenne muscular dystrophy. The company's licensed technology has demonstrated efficacy in…

Articles about Solid Biosciences' IPO: